Core Viewpoint - Brompton Split Banc Corp. has renewed its at-the-market equity program to issue Class A and Preferred Shares, replacing the previous program established in April 2023 [1][2]. Group 1: ATM Program Details - The renewed ATM Program allows the Fund to issue shares at prevailing market prices through the Toronto Stock Exchange or other Canadian marketplaces, with maximum gross proceeds of $75 million for each share class [2][3]. - The program will be effective until June 22, 2027, unless terminated earlier by the Fund, and the volume and timing of distributions will be at the Fund's discretion [3]. Group 2: Investment Portfolio - The Fund invests in a portfolio consisting of common shares of the six largest Canadian banks, with the option to hold up to 10% of total assets in global financial companies for diversification [4]. Group 3: Investment Objectives - The investment objective for Class A Shares is to provide regular monthly cash distributions targeted at least at $0.10 per share and growth in net asset value [5]. - The investment objective for Preferred Shares is to provide fixed cumulative preferential quarterly cash distributions of $0.15625 per share (6.25% per annum) and return the original issue price by November 29, 2027 [6]. Group 4: Performance Metrics - Over the last 10 years, Class A Shares have delivered a 12.0% per annum total return based on NAV, outperforming the S&P/TSX Composite Total Return Index by 3.7% per annum [7][10]. - Preferred Shares have returned 5.3% per annum over the last 10 years, outperforming the S&P/TSX Preferred Share Total Return Index by 1.7% per annum [7][10].

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 333,333 shares of its common stock at the p ...

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug developm ...

BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- CECOCECO, a leading innovator in the lighting and display industry, is excited to announce its participation in the AIA Conference on Architecture & Design 2025, taking place from June 4-7 in Boston. At Booth #1119, CECOCECO will present the latest edition of ArtMorph—an innovative luminous wall panel that seamlessly blends LED display technology with textures. Hosted by the American Institute of Architects (AIA), the conference is one of the industry's most influent ...

ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors will be presented during an oral presentation and poster presentation, respectively, at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

Core Insights - HUTCHMED is set to present new data on its compounds at the ASCO Annual Meeting from May 30 to June 3, 2025, in Chicago, USA [1] Group 1: Savolitinib - The SACHI Phase III study results of savolitinib in combination with osimertinib for EGFR mutation-positive NSCLC will be presented, showing that it met the primary endpoint of progression-free survival (PFS) [2] - Additional data from the SAVANNAH Phase II study indicates that the combination of savolitinib and osimertinib showed better efficacy outcomes compared to savolitinib plus placebo, with promising CNS activity [3] Group 2: Ranosidenib - Results from the Phase I study of ranosidenib (HMPL-306) indicate it was well tolerated, with target inhibition and durable responses, particularly in lower-grade glioma patients, showing an objective response rate (ORR) of 7.1% and a disease control rate (DCR) of 100% [4] Group 3: Fruquintinib - The FRUSICA-1 Phase II study results for fruquintinib plus sintilimab in advanced endometrial cancer patients showed an ORR of 37.0% and a DCR of 88.9%, with durable responses regardless of prior chemotherapy [5] - A Phase IV study involving 2,798 colorectal cancer patients demonstrated a manageable safety profile for fruquintinib, with Grade 3 or above treatment-emergent adverse events occurring in 23.94% for monotherapy and 26.06% for combination therapy [6]

Core Insights - AI-Media Technologies Limited has partnered with Lightning International to enhance accessibility and localization for Free Ad-Supported Television (FAST) channels, aiming to transform content distribution and monetization globally [1][4][11] Group 1: Partnership Overview - The collaboration seeks to break down barriers in entertainment access, allowing for premium content to reach a global audience [1][4] - AI-Media's LEXI and LEXI Translate solutions will provide real-time localization in over 50 languages, making content accessible to diverse viewers [2][11] Group 2: Benefits for FAST Platforms - The partnership enables channels previously limited to English-speaking markets to expand their reach by offering live-translated captions in multiple languages, thus opening new distribution channels [3][11] - Increased engagement and viewership are anticipated as captions enhance viewer retention and ad opportunities on FAST platforms [11] Group 3: Technological Implementation - AI-Media's Alta and LEXI Translate solutions integrate real-time transcription and translation into the linear channel feed, ensuring a cost-effective and reliable workflow [5][11] - The launch of LEXI Voice will provide real-time alternate-language audio tracks, enhancing accessibility for visually impaired audiences [6][11] Group 4: Market Impact - The partnership is expected to create new revenue streams by breaking down language barriers, allowing content owners to tap into previously inaccessible markets [11] - AI-Media's AI-powered solutions offer scalable localization at a fraction of the cost compared to traditional methods, with reduced latency and increased reliability [11]

Core Viewpoint - Reeflex Solutions Inc. has successfully completed its Qualifying Transaction, marking a significant milestone for the company as it transitions to a public entity and aims to enhance its capabilities and resources [3][5]. Group 1: Qualifying Transaction Details - The Qualifying Transaction involved the acquisition of all issued and outstanding shares of Coil Solutions Inc. for a total consideration of $5.8 million, subject to post-closing adjustments [5]. - Reeflex changed its name from "Bigstack Opportunities I Inc." to "Reeflex Solutions Inc." as part of the transaction [3]. - Following the transaction, Reeflex completed a non-brokered private placement of 4,139,500 subscription receipts at $0.20 each, raising gross proceeds of $827,900 [5]. Group 2: Share Structure and Management - As of the completion of the Qualifying Transaction, there are 46,401,500 Reeflex Shares outstanding, with 36,239,500 shares (approximately 78.10%) held by former shareholders of Coil Solutions [6]. - Stock options for 3,050,000 Reeflex Shares were issued to the board and management following the transaction [6]. - The management team includes John Babic as President and CEO, along with other directors and officers [4][5]. Group 3: Trading and Regulatory Information - Trading of Reeflex Shares was halted and is expected to resume under the new ticker symbol "RFX" on the TSXV [2]. - The new CUSIP number for Reeflex Shares is 75846K105, and the new ISIN is CA75846K1057 [2]. Group 4: Auditor Change - Clearhouse LLP has resigned as the auditor of Reeflex, with MNP LLP appointed as the new auditor [11].

Group 1 - Imperial Metals Corporation held its virtual Annual and Special Meeting of Shareholders on May 21, 2025, where nominees listed in the management information circular dated April 4, 2025, were elected as directors [1] - A total of 116,456,204 common shares were voted, representing approximately 71.86% of the issued and outstanding common shares of the Company [2] - The election results showed high approval rates for the directors, with Carolyn D. Anglin receiving 99.97% of votes for, and J. Brian Kynoch receiving 99.99% [2] Group 2 - Imperial is based in Vancouver and is involved in exploration, mine development, and operations, with holdings including the Mount Polley mine (100%), Huckleberry mine (100%), and Red Chris mine (30%) [3] - The Company also has a portfolio of 23 greenfield exploration properties located in British Columbia [3]

Core Points - Swiss Water Decaffeinated Coffee Inc. held its Annual General Meeting of Shareholders on May 22, 2025, where key voting results were announced [1] Group 1: Election of Directors - All Director nominees listed in the Management Information Circular were elected as Directors of Swiss Water, with Frank A. Dennis receiving 98.58% support, and Eric Yanagi receiving 64.37% support [2] Group 2: Appointment of Auditors - MNP LLP was appointed as auditors with a significant voting support of 99.93% [3] Group 3: Company Overview - Swiss Water Decaffeinated Coffee Inc. is recognized as a leading specialty coffee company that utilizes the proprietary Swiss Water® Process for decaffeination without chemical solvents, and it also owns Seaforth Supply Chain Solutions Inc. [4]